D-Galactose - AUG Therapeutics
Alternative Names: AVTX 801; CERC 801; Galactose - AUG TherapeuticsLatest Information Update: 02 Nov 2023
At a glance
- Originator Ichorion Therapeutics
- Developer AUG Therapeutics
- Class Electrolytes; Hexoses; Monosaccharides; Small molecules
- Mechanism of Action Galactose replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glycogen storage disease XIV
Most Recent Events
- 31 Oct 2023 AUG Therapeutics acquires D-Galactose from Avalo Therapeutics
- 28 Mar 2023 No recent reports of development identified for phase-I development in Glycogen-storage-disease-XIV in USA (PO)
- 13 Jan 2023 Mayo Clinic plans a phase II/III trial for Glycogen storage disease XIV (In children, In adolescents, In adults, In the elderly) in May 2023 (PO) (NCT05402384)